Get the Stockscreener App
9.545
3.62%
-0.405
Corbus Pharmaceuticals Holdings Inc stock is traded at $9.545, with a volume of 63,854.
It is down -3.62% in the last 24 hours and down -9.44% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$9.95
Open:
$9.79
24h Volume:
63,854
Relative Volume:
0.26
Market Cap:
$177.31M
Revenue:
$1.54M
Net Income/Loss:
$-78.54M
P/E Ratio:
-1.5967
EPS:
-5.978
Net Cash Flow:
$-64.50M
1W Performance:
-16.10%
1M Performance:
-9.44%
6M Performance:
-18.87%
1Y Performance:
+23.58%
1-Day Range:
$9.55
$10.04
1-Week Range:
$9.55
$12.40
52-Week Range:
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.57 | 184.35M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
440.58 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.14 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
787.07 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.20 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
143.31 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Understanding Momentum Shifts in (CRBP) - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Bd of Directors - Moomoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Octagon/Dr. Jia report 0 shares in Corbus (CRBP) — Schedule 13G/A - Stock Titan
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board - Investing.com UK
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Board, Advances CRB-701 and CRB-913 Clinical Programs - Minichart
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates - TipRanks
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals appoints pharma industry veteran Brent Pfeiffenberger to board of directors - marketscreener.com
Cor appoints Brent Pfeiffenberger to board as independent director - TradingView
Corbus Pharmaceuticals (NASDAQ: CRBP) adds industry veteran to board and expands 2024 equity plan - Stock Titan
HC Wainwright Issues Positive Forecast for CRBP Earnings - MarketBeat
Brokers Offer Predictions for CRBP Q2 Earnings - MarketBeat
CRBP Maintained by Jefferies -- Price Target Lowered to $33.00 - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. schedules corporate overview at RBC and Jefferies healthcare events - Traders Union
CRBP Maintained by Oppenheimer -- Price Target Lowered to $54.00 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP Reiterates by Guggenheim -- Price Target Maintained at $45 - GuruFocus
CRBP: All proposals passed, including annual advisory votes on executive compensation - TradingView
CRBP: All five proposals, including director elections and equity plan amendment, were approved by majority - TradingView
Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating - marketscreener.com
Corbus Pharmaceuticals Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - ChartMill
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.11, Implies 272% Upside - TradingView
Corbus Pharmaceuticals (CRBP) Advances Oncology and Obesity Prog - GuruFocus
Jefferies cuts Corbus Pharmaceuticals stock price target on HNSCC data By Investing.com - Investing.com Canada
Corbus Pharmaceuticals (NASDAQ: CRBP) posts larger Q1 2026 loss but ends quarter with $138M cash - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.44, Implies 275% Upside - TradingView
Corbus Pharmaceuticals Reports Q1 2026 Results: Advances in CRB-701 for Cancer and CRB-913 for Obesity, FDA Alignment, and Upcoming ASCO Data - Minichart
Corbus Pharmaceuticals Holdings, Inc. posts 2026 first quarter financial results and corporate update - Traders Union
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook - TipRanks
Corbus Pharmaceuticals Releases First Quarter 2026 Financial Results and Corporate Update - geneonline.com
Corbus Pharmaceuticals 1Q Loss/Shr $1.23 >CRBP - Moomoo
Corbus (NASDAQ: CRBP) details Q1 loss, FDA alignment and obesity trial - Stock Titan
Corbus Pharmaceuticals Reports FDA Alignment and Positive Developments for CRB-701 and CRB-913 Programs - Quiver Quantitative
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals: Q1 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals 1Q Loss $23M >CRBP - Moomoo
Obesity and cancer drug trials hit key 2026 milestones at Corbus - Stock Titan
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals in Norwood - Boston Real Estate Times
Avoiding Lag: Real-Time Signals in (CRBP) Movement - Stock Traders Daily
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals at 500 River Ridge Drive in Norwood - Colliers
Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting - Traders Union
Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel - Stock Titan
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.93%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):